What question did this study set out to answer?

December 8, 2025BloodOpen Access

Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows efficacy and toxicity of bispecific antibodies in B-cell lymphoma, indicating challenges in clinical practice.

This study aims to evaluate the toxicity, efficacy, and clinical management of bispecific antibodies in routine practice for B-cell lymphoma.
Conducted a retrospective, multicenter study across the GELTAMO network
Included adults with relapsed/refractory B-cell lymphoma treated with CD20/CD3 bispecific antibodies
Analyzed demographics, treatments, toxicities, and clinical outcomes.
Efficacy was lower than in pivotal trials with overall response rates of 43% for LBCL and 75% for FL
Median progression-free survival was 4.0 months for LBCL and 17 months for FL
Toxicity rates were comparable to trials, but higher rates of infections contributed to non-relapse mortality.

Bastos‐Oreiro et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis shows efficacy and toxicity of bispecific antibodies in B-cell lymphoma, indicating challenges in clinical practice.